Company Description
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics.
The company’s in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.
It also focusses on programs comprising hemophilia A and hemophilia B; and research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases.
In addition, the company offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system.
It has license and collaboration agreement with Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies, and co-develop and co-commercialize allogeneic universal CAR-T cell products for an immuno-oncology indication; SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of a variety of B cell-mediated autoimmune diseases; and ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer.
Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
| Country | United States |
| Founded | 2014 |
| IPO Date | May 6, 2016 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 526 |
| CEO | John Leonard |
Contact Details
Address: 40 Erie Street, Suite 130 Cambridge, Massachusetts 02139 United States | |
| Phone | 857 285 6200 |
| Website | intelliatx.com |
Stock Details
| Ticker Symbol | NTLA |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001652130 |
| CUSIP Number | 45826J105 |
| ISIN Number | US45826J1051 |
| Employer ID | 36-4785571 |
| SIC Code | 2835 |
Key Executives
| Name | Position |
|---|---|
| Dr. John M. Leonard M.D. | President, Chief Executive Officer and Director |
| Dr. Laura Sepp-Lorenzino Ph.D. | Executive Vice President and Chief Scientific Officer |
| James E. Basta Esq., J.D. | Executive Vice President, General Counsel and Corporate Secretary |
| Dr. David Lebwohl M.D. | Executive Vice President and Chief Medical Officer |
| Nessan Bermingham Ph.D. | Founder and Member of Scientific Advisor Board |
| Dr. Rachel E. Haurwitz Ph.D. | Co-Founder |
| Dr. Andrew May Ph.D. | Founder and Member of Scientific Advisor Board |
| Dr. Jennifer A. Doudna Ph.D. | Founder and Member of Scientific Advisor Board |
| Dr. Derrick J. Rossi Ph.D. | Founder and Member of Scientific Advisor Board |
| Dr. Rodolphe Barrangou M.B.A., Ph.D. | Founder and Member of Scientific Advisor Board |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 7, 2024 | 10-Q | Quarterly Report |
| Nov 7, 2024 | 8-K | Current Report |
| Oct 25, 2024 | 8-K | Current Report |
| Aug 8, 2024 | 10-Q | Quarterly Report |
| Aug 8, 2024 | 8-K | Current Report |
| Jul 18, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Jun 26, 2024 | 8-K | Current Report |
| Jun 14, 2024 | 8-K | Current Report |
| Jun 13, 2024 | 8-K | Current Report |
| May 9, 2024 | 10-Q | Quarterly Report |